10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
The Latest Analyst Ratings for Sarepta Therapeutics
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Analyst Ratings for Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: Bullish Somewhat Bullish Indifferent…
Catalent’s Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta’s Gene Therapy
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the
Jim Cramer Likes Founder Of AI Company, But Stock Is ‘Losing A Fortune’ And There’s ‘Too Much Hype There’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.
8 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Analyst Ratings for Sarepta Therapeutics
Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell
• GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
What’s Going On With Biotech Contract Service Firm Catalent Stock Today?
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to